Mounjaro and hypoglycaemia: what you need to know

What the trial data says about tirzepatide and hypoglycaemia

The SURMOUNT-1 trial, published in the New England Journal of Medicine, enrolled adults with obesity who did not have diabetes. In that group, documented symptomatic hypoglycaemia was uncommon across all tirzepatide doses. This is consistent with how the drug is designed: tirzepatide stimulates insulin release only when glucose is actually elevated, a property called glucose-dependence. When blood sugar falls toward the lower end of the normal range, that stimulus fades. The body's own counter-regulatory hormones (glucagon, adrenaline) are still free to respond. So for most people taking Mounjaro purely for weight management, a glucose crash is not the primary safety concern.

The picture shifts in people with type 2 diabetes who are already on insulin or a sulphonylurea. Those medicines continue to act regardless of blood-sugar levels, and adding tirzepatide's appetite-reducing effect, plus any caloric restriction, can tip the balance. In the SURPASS diabetes trials, hypoglycaemia rates were meaningfully higher in participants on insulin alongside tirzepatide. The NHS medicines page for tirzepatide flags this combination explicitly, and prescribers routinely consider whether existing diabetes medication needs a dose adjustment before Mounjaro is started.

When hypoglycaemia risk is genuinely elevated on Mounjaro

There is a common misconception that any blood-sugar-lowering medicine must carry a constant risk of hypoglycaemia. With tirzepatide, that is not quite right. The glucose-dependent mechanism provides a built-in buffer. Risk climbs, though, in a handful of situations: concurrent insulin therapy, concurrent sulphonylurea use, significantly restricted caloric intake, strenuous unplanned exercise, or heavy alcohol consumption. If you skip meals or eat far less than usual during the first weeks of treatment, blood sugar can dip more than expected. Tirzepatide also slows gastric emptying, which affects how quickly carbohydrates are absorbed after eating. That is generally helpful for glucose control but can occasionally mean a meal does not raise blood sugar as fast as someone might anticipate if they have already taken rapid-acting insulin.

People who have had bariatric surgery and are also using tirzepatide deserve a mention. Post-surgical hypoglycaemia (sometimes called late dumping) is a separate phenomenon, and the combination warrants close clinical attention. This is one reason why Mounjaro should always be initiated and monitored under prescriber supervision, not taken on the basis of a generic dose guide.

Symptoms to recognise and what to do about them

Hypoglycaemia typically announces itself clearly: shakiness, sweating, pallor, a racing heartbeat, difficulty concentrating, and sometimes hunger that feels sudden and urgent. Mild episodes can usually be treated with fast-acting glucose (glucose tablets, a small glass of fruit juice, or a few jelly sweets) followed by something more sustaining. If someone loses consciousness or cannot swallow safely, that is a medical emergency and the ambulance service should be called immediately.

People on Mounjaro alongside tirzepatide-based therapy who also take insulin are often advised to carry a fast-acting glucose source and, in some cases, to self-monitor blood sugar more regularly, particularly when starting treatment or after a dose increase, including when moving up from the introductory 1.25 mg dose. A prescriber will tailor that advice to the individual. If you are managing another cardiovascular side effect alongside glycaemic changes, you may also find the detail on tirzepatide and low blood pressure useful, since both can sometimes occur around the same period of dose adjustment.

Some people also notice mild dizziness or light-headedness on Mounjaro that is not strictly hypoglycaemia but can feel similar — orthostatic hypotension is one possible explanation, particularly if symptoms appear when standing up quickly. A prescriber can help distinguish the two. For a broader overview of Mounjaro's side-effect profile and eligibility criteria, the weight-loss treatments overview sets out the full clinical picture.

Reporting and aftercare

If you suspect a side effect during treatment, including any episode of low blood sugar, the MHRA's Yellow Card scheme lets patients and carers report directly. This is how regulators track safety signals in real-world use, which matters for a medicine that still carries a Black Triangle (▼) status. It takes two minutes and you do not need a clinical referral to submit.

Mounjaro is a prescription-only medicine that requires a clinical assessment before it is prescribed. If you are wondering whether it is appropriate for your specific situation, including your current medications, starting a free consultation with our prescribers is the right next step. A real clinician reviews your answers the same day (not an algorithm) so questions about combination therapy, existing conditions, and individual risk, including the relationship between Mounjaro and anaemia, are considered properly before any prescription is issued.